Encysive gets $195M offer from Pfizer

02/20/2008 | Houston Chronicle (tiered subscription model) · Forbes

Pfizer on Wednesday announced it intends to acquire Encysive Pharmaceuticals in a $195 million deal that would grant it rights to Thelin, Encysive's treatment for pulmonary arterial hypertension. Thelin is still struggling to obtain FDA approval, but Pfizer's expertise in the market for such treatments is likely to boost the chances of drug candidate to gain regulatory clearance, an analyst said.

View Full Article in:

Houston Chronicle (tiered subscription model) · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX